Last reviewed · How we verify
NCT05539950: COVID-19
Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome
NA trial testing Cardiopulmonary rehabilitation in Post Acute COVID-19 Syndrome. Withdrawn.
31 October 2024
Quick facts
| Lead sponsor | Taipei Medical University Shuang Ho Hospital |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Start date | 1 October 2022 |
| Primary completion | 31 October 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Cardiopulmonary rehabilitation
- Health education
Conditions studied
- Post Acute COVID-19 Syndrome — all drugs for Post Acute COVID-19 Syndrome →
Sponsor
Taipei Medical University Shuang Ho Hospital
Who can join
Adults 20 to 80, any sex, with Post Acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In 2022, though the optimized acute medical treatment of COVID-19 was determined, patients often experience the sequelae (also known as post-acute COVID-19 syndrome, the patients might develop cough, breathlessness, fatigue, weakness, impaired activities of daily livings etc.). Until now, there is no consensus for post-acute COVID-19 syndrome management. Previously, the cardiopulmonary rehabilitation revealed significant benefits in heart failure or chronic obstructive pulmonary disease. The aims of the study are demonstrating the benefits and safety of cardiopulmonary rehabilitations in patients previously admitted to hospital because of COVID-19 with sequelae.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05539950
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiopulmonary rehabilitation
Trials testing the same drug.
- NCT05035797 — CaRe-ECMO Program on ECMO Weaning · NA · unknown
- NCT04668599 — Cardio-pulmonary Rehabilitation and Sleep Quality · completed
Other recruiting trials for Post Acute COVID-19 Syndrome
Currently open trials in the same condition.
- NCT05747534 — AT1001 for the Treatment of Long COVID · Phase 2 · recruiting
Other Taipei Medical University Shuang Ho Hospital trials
Trials by the same sponsor.
- NCT07380685 — On-Demand AI Support Via LINE-Based GPT Assistant to Improve Emotional Resilience and Reduce Burnout Among Clinical Nurs · NA · not yet recruiting
- NCT07435714 — Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid · NA · not yet recruiting
- NCT07230366 — Clinical Validation of AI-powered Smart Vehicle Assisted Gait Training in Neurodegenerative Disorders · NA · not yet recruiting
- NCT07257393 — Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health · not yet recruiting
- NCT07192042 — Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizoph · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05539950 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Shuang Ho Hospital
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05539950.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing